AcquisitionOther
Concentra Biosciences acquired Theseus Pharmaceuticals, Inc.
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Concentra Biosciences -> Theseus Pharmaceuticals, Inc. · $3.90
Theseus has focused on the development of THE-349, a fourth-generation, selective epidermal growth factor receptor inhibitor for C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer, a pan-variant
Open source record (SEC) ↗